In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OncoGenex Technologies Inc.

Division of Achieve Life Sciences Inc.

Latest From OncoGenex Technologies Inc.

Start-Up Previews (9/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cancer Therapeutics, feature Cyclis Pharmaceuticals Inc., Mojave Therapeutics Inc., OncoGeneX Technologies Inc. and Oncologic Inc. Plus these selected Start-Ups across Health Care: CardiacAssist Inc., PharMetrics Inc., Sleep Solutions Inc. and Xoft microTube Inc.

Cancer Therapeutics: Finding a Niche

VCs and CEOs cite the rapid clinical development and recent commercial success of Gleevec and Herceptin as the mere tip of the iceberg of a new generation of gene-based cancer drugs. New treatments are being specifically targeted to genes that up- or down-regulate different characteristics of tumor cells-in particular proliferation, angiogenesis, survival, and apoptosis. We highlight four emerging oncology companies, ranging from firms that have rights to individual compounds against gene targets to those developing broad-based oncology drug delivery platforms.
BioPharmaceutical Business Strategies

OncoGeneX Technologies Inc.

OncoGeneX Technologies was founded specifically to develop OGX-011, a compound that inhibits the production of clusterin, a cell survival protein found to be up-regulated in many cancers after exposure to standard cancer therapies including chemotherapy, radiation therapy, and hormone ablation.

Selected Start-Ups (6/01)

In Vivo summarizes the technologies of several recently founded companies: Archemix Corp. will use its proprietary nucleic acid engineering technology to build protein detection chips and multiplexed assays for use in drug discovery. Gel-Del Technologies Inc. is developing protein-based biomaterials for making implanted medical devices more acceptable to the human body. Neuro Therapeutics Inc. was spun out of the University of British Columbia to commercialize therapies for stimulating repair of injured neurons after traumatic injury of the spinal cord or brain. OncoGenex Technologies Inc. aims to develop and commercialize therapeutics for hormone-independent prostate cancer. Rejuvenon Corp. aims to turn back the hands of time with drugs to treat or prevent disorders related to aging. A new entrant in the cardiovascular diagnostics arena, Belgium's Thermocore Medical Systems NV is developing a thermographic catheter-based system to localize and visualize unstable coronary plaque.
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Achieve Life Sciences Inc.
  • Senior Management
  • Scott D Cormack, Pres. & CEO
    Martin Gleave, CSO
  • Contact Info
  • OncoGenex Technologies Inc.
    Phone: (604) 736-3678
    1001 W. Broadway
    Ste. 400
    Vancouver, V6H 4B1